SCHEMBL5036192

SCHEMBL5036192

COc1ccc(C2CCOCC2)c2oc(NC(=O)c3ccnc(Br)c3)nc12

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.76
ADORA1 P30542 1/20 0.76
CASP3 P42574 1/20 0.37
CDK9 P50750 1/20 0.37
CASP7 P55210 1/20 0.37
RAF1 P04049 9/20 0.37
LMNA P02545 2/20 0.36
MAPT P10636 1/20 0.36
TP53 P04637 1/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
GAA P10253 1/20 0.35
LRRK2 Q5S007 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5036467 0.90 ADORA2A (0.77) ADORA2AADORA1CASP3CDK9CASP7
SCHEMBL5033976 0.87 ADORA2A (0.73) ADORA2AADORA1CASP3CDK9CASP7
SCHEMBL5042972 0.87 ADORA2A (0.73) ADORA2AADORA1CASP3CDK9CASP7
SCHEMBL5033977 0.86 ADORA2A (1.00) ADORA2AADORA1RAF1MAPTKMT2A
SCHEMBL5037854 0.83 ADORA2A (0.66) ADORA2AADORA1LMNAMAPTKMT2A
SCHEMBL6178935 0.82 ADORA2A (0.53) ADORA2AADORA1LMNAMAPTTP53
SCHEMBL5036181 0.82 ADORA2A (0.66) ADORA2AADORA1LMNAMAPTKMT2A
SCHEMBL20794981 0.82 ADORA2A (0.53) ADORA2AADORA1CASP3CDK9CASP7
SCHEMBL5036100 0.81 ADORA2A (0.63) ADORA2AADORA1MAPTKMT2AMEN1
SCHEMBL30609156 0.80 ADORA2A (0.51) ADORA2AADORA1CASP3CDK9CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1587799-B1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS HOFFMANN LA ROCHE (CH) 2008-03-12 EP disclosed
US-6992083-B2 deiodination/arylation, acylation or hydrogenation of a substituted 4-methoxy-bezoxazole derivative; adenosine receptor ligands; Parkinson's and Alzheimer's Diseases; 2-Chloromethyl-N-[7-(4-fluoro-phenyl)-4-methoxy-benzooxazol-2-yl]-isonicotinamide HOFFMAN-LA ROCHE INC. (US) 2006-01-31 US disclosed
EP-1587799-A1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-26 EP disclosed
US-20040152702-A1 Benzoxazol derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-08-05 US disclosed
WO-2004063177-A1 BENZOXAZOLE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152702-A1 Benzoxazol derivatives P2RX3, P2RX2, P2RX1 ADORA2A 11/4885ADORA1 8/4885CASP3 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.